Free Trial
NASDAQ:NAOV

Nanovibronix 4/8/2024 Earnings Report

Nanovibronix logo
$0.83 0.00 (-0.48%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$0.84 +0.01 (+0.60%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nanovibronix EPS Results

Actual EPS
-$4.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nanovibronix Revenue Results

Actual Revenue
$1.18 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nanovibronix Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nanovibronix's next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Nanovibronix Earnings Headlines

NanoVibronix Appoints New Executive VP of Finance
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
See More Nanovibronix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nanovibronix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nanovibronix and other key companies, straight to your email.

About Nanovibronix

Nanovibronix (NASDAQ:NAOV), through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

View Nanovibronix Profile

More Earnings Resources from MarketBeat